40Hz tACS in Treating Cognitive Function and Modulating Neurophysiology of Patients With Alzheimer's Disease

Che-Sheng Chu

Status: Enrolling

Conditions: Alzheimer Disease

Treatments: Device: sham tACS; Device: active tACS

Study type: Interventional

Funder types: Other

Identifiers

NCT05723172

VGHKS-112-01

Details and patient eligibility

About

Gamma brain activity is crucial for cognitive function and intra-brain communication. Gamma frequency stimulation via transcranial alternating current stimulation(tACS) might alleviate memory deficits on both animal models of Alzheimer's disease (AD) and clinical trial. The study aims to assess the safety and efficacy of tACS on cognitive function and modulating neurophysiology in patients with AD.

Full description

Gamma brain activity is crucial for cognitive function and intra-brain communication. Gamma frequency stimulation via transcranial alternating current stimulation(tACS) might alleviate memory deficits on both animal models of Alzheimer's disease (AD) and clinical trial. The study aims to assess the safety and efficacy of tACS on cognitive function and modulating neurophysiology in patients with AD.

40mins 10Hz-tACS for daily consecutive sessions will be given.

Enrollment: 48 estimated patients

Sex: All

Ages: 60 to 90 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• aged 60- to 90-year-old
• clinical dementia rating scale (CDR) of 1 or mini-mental state examination (MMSE) score of 18 to 26.
• Participants were allowed to maintain their anti-dementia medications without changes from at 3 months before and throughout the study.

Exclusion criteria

• having contraindications for tACS, e.g., implanted brain medical devices or mental in the head, having arrhythmia and with pacemaker implantation, having history of seizures, having history of intracranial neoplasms or surgery, or severe head injuries or cerebrovascular diseases
• clinical depression measured by Hamilton depression rating scale score equal and over 17

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: Triple Blind

---

48 participants in 2 patient groups

active tACS

Active Comparator group

Description:

40 mins tACS for 10 consecutive daily sessions

Treatment:

Device: active tACS

sham tACS

Sham Comparator group

Description:

40 mins sham tACS for 10 consecutive daily sessions

Treatment:

Device: sham tACS